Vnitr Lek 2020, 66(3):e38-e40 | DOI: 10.36290/vnl.2020.057

Importance of breath tests for the evaluation liver function in patients with chronic kidney disease

Nikola Mejzlíková1, Karolína Krátká1, Miluše Vejvodová1, Pavla Libicherová1, Nikola Uzlová1, Jana Vránová2, Ivan Rychlík1
1 I. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
2 Ústav lékařské biofyziky a lékařské informatiky 3. LF UK Praha

Breath tests for the evaluation liver metabolic function are a non-invasive diagnostic method with high sensitivity and specificity. Up today, the issue of liver damage in patients with chronic kidney disease has not been investigated sufficiently, although it might have significant clinical consequences. The following article describes the principles of breath tests, experiences with breath tests in patients with chronic kidney disease (CKD) and the results of our pilot study with methacetin breath tests in patients with CKD and in regular peritoneal dialysis treatment.

Keywords: 13C‑methacetin breath test, chronic kidney disease, kidney‑liver organ cross talk, metabolic liver function.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mejzlíková N, Krátká K, Vejvodová M, Libicherová P, Uzlová N, Vránová J, Rychlík I. Importance of breath tests for the evaluation liver function in patients with chronic kidney disease. Vnitr Lek. 2020;66(3):e38-40. doi: 10.36290/vnl.2020.057.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther 2002; 16: 1977-1996. Go to original source... Go to PubMed...
    2. Matsumoto K, Suehiro M, Iio M, et al. 13C)methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987; 32: 344-348. Go to original source... Go to PubMed...
    3. Leblond F, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-1320. Go to original source...
    4. Leblond F, Guévin C, Demers C, et al. Downregulation of hepatic cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 236-232. Go to original source...
    5. Guévin C, Michaud J, Naud J, et al. Down‑regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002; 137: 1039-1046. Go to original source... Go to PubMed...
    6. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A aktivity in patients with end‑stage renal disease. Clin Pharmacol Ther 2003; 73: 427-434. Go to original source... Go to PubMed...
    7. Nolin TD, Appiah K, Kendrick SA, et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006; 17: 2363-2367. Go to original source... Go to PubMed...
    8. Michaud J, Nolin TD, Naud J et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108: 157-163. Go to original source... Go to PubMed...
    9. Michaud J, Dubé P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005; 144: 1067-1077. Go to original source... Go to PubMed...
    10. Joy MS, Frye RF, Nolin TD, et al. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy 2014; 34: 114-122. Go to original source... Go to PubMed...
    11. Michaud J, Naud J, Chouinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006; 17: 3041-3048. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.